MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Diuretic May Not Be Best Way To Reduce Chf

Back to heart news Blogs list Cancer blog  


Subscribe To Heart News RSS Feed  RSS content feed What is RSS feed?

Diuretic May Not Be Best Way To Reduce Chf

Diuretic May Not Be Best Way To Reduce Chf
Scientists believe they may have identified a new agent to reduce the excess fluid build-up in patients with congestive heart failure, one that avoids the relative sodium-depleting effects of diuretics, now the most usually used drugs for this purpose.

The drug under investigation, called lixivaptan, appears to be just as effective as a diuretic in helping patients get rid of excess water and has the added benefit of retaining proper levels of sodium in the body, said Dr. William Abraham, director of cardiovascular medicine at Ohio State University Medical Center and lead author of a study of this drug.

The study results are reported in the April 18 issue of the Journal of the American College of Cardiology. Abraham will also serve as the international principal investigator of an upcoming multicenter Phase 3 trial to further evaluate the effectiveness of the drug.

Diuretics become part of life for a number of patients with congestive heart failure, a disease characterized by fluid retention that can lead to shortness of breath, swollen legs and ankles, and progressive weakening of the heart. Though they are key to reducing fluid, diuretics can cause the kidneys to excrete more sodium than water, which can have damaging effects. An abnormally low concentration of sodium in the blood leads to another chronic condition called hyponatremia, which can slow thinking and cause memory problems, and indicates a poor prognosis for patients with heart failure.

Lixivaptan acts by blocking vasopressin, an anti-diuretic hormone that causes the kidneys to retain water. When the body needs to remain hydrated under certain conditions, vasopressin can have protective effects. But an excess of vasopressin is counterproductive in a body retaining too much fluid, Abraham said.

"This drug is a vasopressin receptor antagonist, so it signals the kidneys to excrete water, not salt," said Abraham, who is also associate director for clinical/translational research at Ohio State's Davis Heart and Lung Research Institute. "It shifts the balance of water and electrolytes to a more favorable state, keeps sodium in and reduces other adverse effects on kidney function. It could be a great adjunct to therapy in heart failure patients with fluid retention."

The study involved 42 patients with class II or class III congestive heart failure, meaning they experienced mild to marked limitation of activity and were generally able to engage in only mild exertion. Of those, 30 patients took varying doses of lixivaptan and 12 patients received a placebo.

At every dose but the lowest (10 milligrams), lixivaptan produced a significant increase in urine volume over four hours when compared to placebo, and over 24 hours, the output ranged from 1.8 liters in the placebo group to 3.9 liters in patients receiving 400 milligrams of lixivaptan. In addition, lixivaptan dramatically increased solute-free water excretion - meaning the urine from patients taking the drug removed more water than sodium from the body.

The apparent effectiveness of the drug not only holds promise as a new therapy for heart failure patients, but also helps clarify the role vasopressin appears to play in the water retention and low sodium concentration in the first place, Abraham said. He and his colleagues suggested that a vasopressin antagonist may also be useful in treating hyponatremia that occurs in heart failure patients who are not taking diuretics but who still experience its effects because of an imbalance of water and salt.

About 90 percent of hospitalizations associated with heart failure are correlation to water retention. Typically congestive heart failure affects an estimated 5 million americans, and is characterized by a reduced ejection fraction - a measurement of how well the heart is squeezing - and often by this seepage of fluid into the lungs, feet, legs or abdominal cavity.



Posted by: Daniel    Source




Did you know?
Scientists believe they may have identified a new agent to reduce the excess fluid build-up in patients with congestive heart failure, one that avoids the relative sodium-depleting effects of diuretics, now the most usually used drugs for this purpose. The drug under investigation, called lixivaptan, appears to be just as effective as a diuretic in helping patients get rid of excess water and has the added benefit of retaining proper levels of sodium in the body, said Dr. William Abraham, director of cardiovascular medicine at Ohio State University Medical Center and lead author of a study of this drug.

Medicineworld.org: Diuretic May Not Be Best Way To Reduce Chf

Aggressive heart therapies still underused| Aspirin might prevent vioxx cardiac damage| Bariatric surgery to control weight in cardiac patients| Black immigrants from africa arrive healthier than those from europe| Exercise stress management gives physiological benefits for heart patients| Heart and cell signaling| Link between obesity inflammation and vascular disease found| Pig hearts in nonhuman primates a success story| Strategies to raise hdl cholesterol levels| Stress test identifies high risk people for coronory heart disease|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.